Emily Singler, VMD, shares that for the first time the FDA has granted full approval for an indication for an animal drug that was previously approved under the FDA’s expanded conditional approval authority. Vetmedin® (pimobendan) Chewable Tablets label has officially expanded to include an indication for the delay of the onset of congestive heart failure in dogs with stage B2 preclinical myxomatous mitral valve disease.
Source: AAHA Trends, FDA, Boehringer-Ingelheim, January 7, 2026. Link. Stage B2 refers to dogs with no clinical signs of heart disease but with a moderate to loud mitral murmur due to mitral valve regurgitation and cardiomegaly.
Full prescribing information for Chewable Tablets <Link>.